The consistent late-stage program wins (seven in seven months) suggest strong customer demand and revenue visibility for Lifecore's CDMO services. Monitor upcoming quarterly filings for revenue recognition from these contracts and any new customer announcements. The neurology product win adds diversification to the pipeline.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 15 $5.49entry
- T+1 · 5mo ago −2.55%α −1.95% · $5.35
- T+5 · 5mo ago +0.73%α +2.11% · $5.53
- T+20 · 4mo ago −15.66%α −14.91% · $4.63
- T+60 · 2mo ago −25.50%α −26.50% · $4.09
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Lifecore Biomedical announced a new commercial manufacturing agreement with an unnamed global pharmaceutical company for an injectable neurology product. This marks the seventh late-stage program win in seven months, signaling strong business development momentum for the CDMO.
Key Facts
- New agreement with a global pharma company for tech transfer and commercial manufacturing of an injectable suspension product for neurological disorders
- Seventh late-stage program win in the last seven months
- Product is a higher-viscosity suspension formulation requiring specialized manufacturing expertise
- Contract is with an undisclosed global pharmaceutical company (counterparty name not disclosed)
Financial Impact
Revenue contribution and contract value not disclosed; seven late-stage wins in seven months indicate accelerating commercial pipeline growth
Risk Factors
- Counterparty and deal financial terms undisclosed, making revenue impact unclear
- Late-stage programs may not all reach commercial launch if customers fail to obtain regulatory approval
- Customer concentration risk if agreements are with a small number of large pharma partners
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3311684 |
Track record
20 reports on LFCR
6 of 8 bullish or bearish reports moved the stock their way by T+1. Best: +45.27% at T+60 after the Mar 26, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $6.42 Now $6.42 +0.08% settles Nov 18
- Nov 13, 20263d ago DEFM14A Neutral 6/10 Entry $6.42 Now $6.42 +0.00% settles Nov 17
- Nov 5, 202611d ago 8-K / DEFA14A Neutral 5/10 Entry $6.40 to $6.36 Now $6.42 +0.31% ▼ −0.63% −0.94% vs SPY
- Nov 4, 202612d ago 8-K Bearish 6/10 No price data
- Nov 4, 202612d ago Press Release Bearish 5/10 Entry $6.44 to $6.40 Now $6.42 +0.31% ▲ +0.62% −3.79% vs SPY
- Oct 30, 202617d ago PREM14A Neutral 5/10 Entry $6.39 to $6.42 Now $6.42 +0.47% ▲ +0.47% +0.17% vs SPY
- Oct 20, 202627d ago 8-K Neutral 3/10 Entry $6.37 to $6.37 Now $6.42 +0.78% · 0.00% +1.18% vs SPY
- Sep 28, 20267w ago SC 13D/A Bullish 7/10 Entry $6.59 to $6.58 Now $6.42 −2.58% ▼ −0.15% +0.05% vs SPY
- Sep 28, 20267w ago DEFA14A Bullish 7/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
- Sep 28, 20267w ago 8-K Bullish 8/10 Entry $6.52 to $6.59 Now $6.42 −1.53% ▲ +1.07% +1.26% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers